GeneHarmonics Inc. is helping to develop population-based studies that can help collect data points to better understand infectious diseases that can hopefully be used to develop predictive models to fight them.
The pilot will be designed around studies for Malaria - considered the number one killer in the world. The importance of this project cannot be understated. For the first time, a multi-sectoral initiative shall be deploying the convergence of 3 technologies - Quantum Dots bio-diagnostics, Secured Data Systems, and Drug Delivery Systems. The groups who signed up to participate in the project includes: (a) the Asian office representing a global company with presence in more than 72 countries, (2) one of the leading world experts in the field of entomology and eco-toxicology, (3) an Asia-based non-profit organization who specializes in operationalizing community-based projects and who has affiliations with international organizations with a combined presence in more than 100 countries. (4) US scientists, and (5) Organizations who have been working on the eradication of Malaria in Africa.
The population study shall create a working model based on the following targeted milestones: the collection of diagnostics data from a large number of people in a community to study trends of Malaria-associated biomarkers in individuals; Develop and launch a secured data platform that anonymize data and integrate the same to IOT sensors.
Challenges We Can Overcome
There are several challenges the we are looking to overcome simply by the composition of our team, the depth of our technologies, and the strength of our strategic partners. Our Quantum Dot diagnostic devices are portable, rapid and quantitative making it deployable to populations that are being studied - the diagnostics can be arranged to come to community centers and/or even houses. Rapid, quantitative and portable means getting the whole population tested including those that are asymptomatic persons who are, unknowingly, vectors of the pathogens themselves. The data platform will give us insights on how aggregated and filtered information can be used to track the movement of pathogens within a large community. AADC has been organizing community-based projects for more than 20 years - at times in partnership with the likes of CARE Org (present in 100 countries) and OXFAM (present in several countries as well. The professional services that ManpowerGroup will lend to the project only assures the fidelity of the data collection activities.
We have the foundational technology to develop rapid and quantitative diagnostic tests for different biomarkers using Quantum Dots. Our patented Quantum Dot technology makes our diagnostic tests ideal for immunity level detection, infectious disease management, and biomarker monitoring in both personal health and drug delivery technology.
A companion to our Quantum Dot technology is a secured, encrypted data platform. Our platform captures and organizes the data necessary to monitor biomarker trends in personal health, expedite drug development through biomarker tracking, and anonymize positive or negative results in infectious disease management.
We are partnering with several pharmaceutical companies to develop novel drug delivery systems. Through our Quantum Dot diagnostic technology and our data collection platform we can expedite new drugs with higher bioavailability of active pharmaceutical ingredients (API) and substantially reduced toxicity and side effects.